8
Participants
Start Date
June 9, 2025
Primary Completion Date
December 30, 2025
Study Completion Date
December 30, 2025
Esketamine (Intranasal Spray)
Esketamine doses will be administered via insufflation with a starting dose of 1 spray of 14 mg per nostril (28 mg/total). Based on tolerability, total dose will be increased to a target dose of 84 mg delivered as three bouts separated by 5 minutes per bout (total dose administered in 15 minutes).
Massed Prolonged Exposure (PE)
Eligible participants will be enrolled to receive 10 sessions of PE delivered in massed (daily) format over 2 weeks (weekdays, not including weekends and holidays)
RECRUITING
The University of Texas Health Science Center at San Antonio, San Antonio
Institute for Integration of Medicine & Science-UT Health San Antonio
UNKNOWN
The University of Texas Health Science Center at San Antonio
OTHER